Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- What Lilly Learned From Steak n Shake: A Q&A on Cymbalta
- Eli Lilly’s Cymbalta is fast adding indications. Today the company announced the results of a trial to see if the drug can be used for back pain and last week it was approved in Europe for generalized anxiety disorder. Its wide variety of uses --...
- Blog posts 2008-08-25
Additional Resources
- FDA Approves Cymbalta(R) for the Management of Fibromyalgia
- The U.S. Food and Drug Administration FDA has approved Cymbalta® duloxetine HCl for the management of fibromyalgia, a chronic widespread pain disorder, Eli Lilly and Company (NYSE: LLY) announced today. Cymbalta is the first serotonin-norepinephrine reuptake inhibitor with proven efficacy for reducing pain in patients with fibromyalgia. The fibromyalgia indication...
- Research articles 2008-06-16
- Eli Lilly and Company. (Active Pharmaceutical Ingredient Watch).(receives letter of approval to market Cymbalta)(Brief Article)
- ELI LILLY and Company received an approvable letter from the Food and Drug Administration fur Cymbalta duloxetine, a ... ELI LILLY and Company received an approvable letter from the Food and Drug Administration fur Cymbalta duloxetine, a dual reuptake inhibitor that works through two...
- Research articles 2002-09-23
- FDA Approves Cymbalta(R) for Treatment of Generalized Anxiety Disorder
- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration FDA has approved the antidepressant Cymbalta® duloxetine HCl for the treatment of generalized anxiety disorder GAD, a condition that affects more than 6.5 million American adults in a given year(1). Because GAD presents with a...
- Research articles 2007-02-26
- FDA to Lilly: Can Cymbalta journal ads
- THE FDA called on Eli Lilly to stop journal ads for Cymbalta as a treatment for nerve pain caused by diabetes because the ads fail to address drug risks.
- Research articles 2005-12-01
- Eli Lilly expects approval on Cymbalta
- AS A POSSIBLE indication that its manufacturing problems will soon be cleared up, Eli Lilly executives reported that the company expects approval from the FDA for its antidepressant Cymbalta in the fourth quarter.
- Research articles 2003-07-01
- Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
- Eli Lilly and Company (NYSE: LLY) has submitted a supplemental New Drug Application sNDA to the U.S. Food and Drug Administration FDA seeking approval for a new indication for Cymbalta® duloxetine HCl for the management of chronic pain, the company announced today. The submission is based on outcomes of...
- Research articles 2008-05-29
- Lilly's promo deal with CVS draws fire
- Eli Lilly is catching heat for paying CVS Caremark to promote its Cymbalta drug to doctors. The CVS pharmacy benefits manager has been sending promotional materials to doctors, touting Cymbalta for its new indication as a fibromyalgia treatment. The promos come under the guise of professional advice--"We are committed to...
- News items 2009-10-19
- BNET Focus on Antidepressants: Part 1, Sales and Strategy
- Ever since Eli Lilly launched Prozac in the U.S. in 1987, Americans have had a love affair with anti-depressants. Prozac isn't just a pill. It was the cultural touchstone of 1990s -- as a lifesaver, punchline and punching bag. When Prozac went off-patent in 2001, something interesting...
- Blog posts 2008-09-30
- BNET Focus on Antidepressants: Part 3, the Future
- The future for branded antidepressants as a business looks grim. Here's the current patent expiration schedule for the four biggest sellers: GlaxoSmithKline's Paxil CR expires in 2008 Wyeth's Effexor XR expires in 2011 Forest Labs' Lexapro expires in 2012 Eli Lilly's Cymbalta expires in...
- Blog posts 2008-10-02
- Forest Laboratories Inc. F3Q08 (Qtr End 12/31/07) Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions. Your first question comes from the line of Rich Silver of Lehman Brothers. Rich Silver Lexapro and market share expectations in the past, I think you have said that you had hoped to gain modest market share overtime. Now that there is no longer...
- Earnings calls 2008-01-15
- Eli Lilly Q3 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions Our first question comes Roopesh Patel with UBS please go ahead. Roopesh Patel - UBS Thank you. I have a couple of questions, first on Cymbalta. In light of the recent slowdown in market share trends over the past five months, I was just wondering,...
- Earnings calls 2007-10-18
- Eli Lilly & Co. Q4 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. Operator Instructions. Our first question comes from the line Tim Anderson with Sanford Bernstein. Please go ahead. Jay Olsen - Sanford Bernstein Good morning, this is Jay Olsen for Tim Anderson. I have two questions. First, can you update us on what impact you might...
- Earnings calls 2009-01-29
- FDA Issues Approvable Letter for Lilly's Cymbalta for Treatment of Depression; From the Makers of Prozac, Cymbalta Will Offer New Hope for Those With Depression, When Approved
- Business & Health/Medical Editors
- Research articles 2002-09-16
- Eli Lilly Q2 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions And our first question comes from the line of James Kelly of Goldman Sachs. Please go ahead. James Kelly - Goldman Sachs Thank you and good morning. My question relates to Zyprexa and the depot formulation, and thank you for the additional data in Canada...
- Earnings calls 2007-07-24
- A Lilly-ImClone Deal May Offer the Drama that CEO Lechleiter Craves
- Today came the news that Eli Lilly is one of the mystery suitors in the ImClone deal that Bristol-Myers Squibb was just booted from. If CEO John Lechleiter were to scoop up ImClone -- thus bolting on the cancer specialist's pipeline to replace the absence of its...
- Blog posts 2008-09-29
- Insomnia and Antidepressant Sales Give Lie to DTC Myths
- Direct-to-consumer drug advertising has almost no relationship with consumer demand for prescriptions. That is one interpretation of a story in Ad Age showing that scrips for insomnia pills (such as Sanofi-Aventis's Ambien CR) and antidepressants (such as Eli Lilly's Cymbalta) are up, even though advertising in both those categories is...
- Blog posts 2009-03-05
- Hulu Is Starting to Show Itself the Money
- This afternoon, I tested out a theory that I've had a few months now: that Hulu is finally really beginning to sell inventory. Time was, as many of you know, that the site was chock full of public service ads, even on its most highly trafficked content; today, in a...
- Blog posts 2009-10-15
- Lilly Profit Tops Estimates on Drug Sales, Taxes
- By Lewis Krauskopf NEW YORK (Reuters) - Eli Lilly and Co LLY posted third-quarter profit well above Wall Street expectations on Wednesday on strong performance of its major prescription drugs and lower taxes, sending shares up 1.9 percent. Sales of lung cancer treatment Alimta, anti-depressant Cymbalta, Humalog insulin and schizophrenia...
- News items 2009-10-21
- Ask Your Doctor If This Ad Is Right for You
- By Arlene Weintraub Does it seem like you hear the phrase "ask your doctor" every time you turn on the TV? There's a reason. Drug companies spend about $5 billion a year in the U.S. on ads imploring people to talk to their physicians if they think a pill they've...
- News items 2009-11-05
- << Previous
- page 1 of 1
- Next >>
